## Surrey M Walton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1177057/publications.pdf

Version: 2024-02-01

471509 501196 60 960 17 28 citations h-index g-index papers 60 60 60 1284 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Mavacamten for hypertrophic cardiomyopathy: effectiveness and value. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 369-375.	0.9	2
2	Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off. Quality of Life Research, 2021, 30, 1433-1444.	3.1	19
3	Increasing respondent engagement in composite time trade-off tasks by imposing three minimum trade-offs to improve data quality. European Journal of Health Economics, 2021, 22, 17-33.	2.8	2
4	The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 667-673.	0.9	3
5	Type 2 diabetes mellitus burdens among adults with sickle cell disease: A 12â€year single health systemâ€based cohort analysis. EJHaem, 2021, 2, 97-101.	1.0	O
6	Antidiabetic drug use trends in patients with type 2 diabetes mellitus and chronic kidney disease: A crossâ€sectional analysis of the National Health and Nutrition Examination Survey. Journal of Diabetes, 2020, 12, 385-395.	1.8	13
7	Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 67-75.	0.9	6
8	Estimating the Impact of Food and Drug Administration's Unapproved Drug Initiative on Drug Prices and Sales. Therapeutic Innovation and Regulatory Science, 2020, 54, 424-430.	1.6	3
9	Implementation Lessons From a Randomized Trial Integrating Community Asthma Education for Children. Journal of Ambulatory Care Management, 2020, 43, 125-135.	1.1	6
10	Evaluating a remote patient monitoring program for automated peritoneal dialysis. Peritoneal Dialysis International, 2020, 40, 377-383.	2.3	15
11	Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group. Value in Health, 2020, 23, 529-539.	0.3	59
12	The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 361-366.	0.9	4
13	Racial and ethnic disparity in palliative care and hospice use. American Journal of Managed Care, 2020, 26, e36-e40.	1.1	24
14	Understanding Student Preferences in the Selection of a Graduate Allied Health Program: A Conjoint Analysis Study. Journal of Allied Health, 2020, 49, 208-214.	0.2	1
15	Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner <i>etÂal</i> British Journal of Haematology, 2019, 186, 782-783.	2.5	О
16	Leveraging system sciences methods in clinical trial evaluation: An example concerning African American women diagnosed with breast cancer via the Patient Navigation in Medically Underserved Areas study. Contemporary Clinical Trials Communications, 2019, 15, 100411.	1.1	4
17	Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a sixâ€year populationâ€based cohort analysis. British Journal of Haematology, 2019, 185, 116-127.	2.5	14
18	A Multifaceted Intervention to Improve Patient Knowledge and Safe Use of Opioids: Results of the ED EMC <sup>2</sup> Randomized Controlled Trial. Academic Emergency Medicine, 2019, 26, 1311-1325.	1.8	15

#	Article	IF	CITATIONS
19	Lifestyle-related attitudes: do they explain self-rated health and life-satisfaction?. Quality of Life Research, 2018, 27, 1227-1235.	3.1	10
20	Promoting Seniors' Health With Home Care Aides: A Pilot. Gerontologist, The, 2018, 58, 779-788.	3.9	16
21	Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. Medical Decision Making, 2018, 38, 968-982.	2.4	25
22	Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome. Journal of Managed Care & Decialty Pharmacy, 2018, 24, 800-812.	0.9	3
23	Type 2 Diabetes Mellitus in Patients with Sickle Cell Disease: A Population-Based Longitudinal Analysis of Three Cohorts. Blood, 2018, 132, 4817-4817.	1.4	2
24	High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy. Journal of Thrombosis and Thrombolysis, 2017, 44, 435-441.	2.1	22
25	Economic Impact of a Peritoneal Dialysis Continuous Quality Improvement Program in Colombia. Peritoneal Dialysis International, 2017, 37, 165-169.	2.3	15
26	Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 57-63.	0.9	29
27	Considering Recent Trends in Healthcare Labor Markets in Educational Program Planning in Allied Health. Journal of Allied Health, 2017, 46, 197-202.	0.2	3
28	CONTEMPORARY TRENDS AND PREDICTORS OF ANTIPLATELET AGENT USE IN PATIENTS WITH ACUTE CORONARY SYNDROME FOLLOWING PERCUTANEOUS CORONARY INTERVENTION. Journal of the American College of Cardiology, 2016, 67, 538.	2.8	0
29	Financial Implications to Medicare from Changing the Dialysis Modality Mix under the Bundled Prospective Payment System. Peritoneal Dialysis International, 2014, 34, 749-757.	2.3	29
30	A trial of indication based prescribing of antihypertensive medications during computerized order entry to improve problem list documentation. International Journal of Medical Informatics, 2013, 82, 996-1003.	3.3	20
31	Pharmacy practice in small and rural hospitals in Illinois—2011. American Journal of Health-System Pharmacy, 2013, 70, 1144-1152.	1.0	3
32	Survey of pharmacy staffing levels and vacancy rates in small and rural hospitals in Illinois. American Journal of Health-System Pharmacy, 2013, 70, 1392-1396.	1.0	2
33	Comparison of pharmacy services at critical access hospitals and other rural and small hospitals in Illinois. American Journal of Health-System Pharmacy, 2013, 70, 1313-1321.	1.0	1
34	Economic Burden of Incident Unplanned Starts on Peritoneal Dialysis in a High Specialty Health Care Facility in Mexico City. Value in Health Regional Issues, 2012, 1, 184-189.	1.2	4
35	Estimating DEA confidence intervals with statistical panel data analysis. Journal of Applied Statistics, 2012, 39, 815-828.	1.3	7
36	The Impact of Medicare Part D on Out-of-Pocket Costs for Prescription Drugs, Medication Utilization, Health Resource Utilization, and Preference-Based Health Utility. Health Services Research, 2011, 46, 1104-1123.	2.0	37

#	Article	IF	CITATIONS
37	Improving the Efficiency of Distributive and Clinical Services in Hospital Pharmacy. Journal of Medical Systems, 2011, 35, 59-70.	3.6	15
38	Measuring Hospital Efficiency with Data Envelopment Analysis: Nonsubstitutable vs. Substitutable Inputs and Outputs. Journal of Medical Systems, 2011, 35, 1393-1401.	3.6	34
39	Statistical implications of utility weighted and equally weighted HRQL measures: an empirical study. Health Economics (United Kingdom), 2010, 19, 101-110.	1.7	16
40	Cost analysis of flavocoxid compared to naproxen for management of mild to moderate OA. Current Medical Research and Opinion, 2010, 26, 2253-2261.	1.9	6
41	Data envelopment analysis: A method for comparing hospital pharmacy productivity. American Journal of Health-System Pharmacy, 2009, 66, 1660-1665.	1.0	10
42	Association between hospital size and pharmacy department productivity. American Journal of Health-System Pharmacy, 2007, 64, 937-944.	1.0	25
43	Pharmacy staffing and productivity. American Journal of Health-System Pharmacy, 2007, 64, 2323-2324.	1.0	3
44	Cost analysis of divalproex sodium extended-release compared to valproic acid in the treatment of bipolar disorder. Current Medical Research and Opinion, 2007, 23, 1997-2004.	1.9	4
45	Monitoring of pharmacy staffing, workload, and productivity in community hospitals. American Journal of Health-System Pharmacy, 2006, 63, 1728-1734.	1.0	29
46	Factors that influence prescribing within a therapeutic drug class. Journal of Evaluation in Clinical Practice, 2005, 11, 357-365.	1.8	12
47	New Entry and the Rate of Return to Education: The Case of Registered Nurses. Atlantic Economic Journal, 2005, 33, 325-336.	0.5	2
48	Update on the pharmacist shortage: National and state data through 2003. American Journal of Health-System Pharmacy, 2005, 62, 492-499.	1.0	50
49	A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data. Fertility and Sterility, 2005, 83, 804-807.	1.0	17
50	Factors that Influence Prescribing Decisions. Annals of Pharmacotherapy, 2004, 38, 557-562.	1.9	90
51	Impact of Prescribing Guidelines for Inpatient Anticoagulation. Annals of Pharmacotherapy, 2004, 38, 1570-1575.	1.9	11
52	The Pharmacist Shortage and Medication Errors: Issues and Evidence. Journal of Medical Systems, 2004, 28, 63-69.	3.6	18
53	Cardiovascular risks in firefighters: implications for occupational health nurse practice. AAOHN Journal, 2004, 52, 66-76.	0.5	14
54	Cause, type, and workers' compensation costs of injury to fire fighters. American Journal of Industrial Medicine, 2003, 43, 454-458.	2.1	104

#	Article	IF	CITATIONS
55	Monitoring Costs and Tolerance Levels for Classroom Cheating. American Journal of Economics and Sociology, 2003, 62, 713-719.	0.8	7
56	Pharmaceutical services in rural hospitals in Illinoisâ€"2001. American Journal of Health-System Pharmacy, 2003, 60, 666-674.	1.0	11
57	Survey of hospital policies regarding low-molecular-weight heparins. American Journal of Health-System Pharmacy, 2002, 59, 534-538.	1.0	12
58	The Bias Against New Innovations in Health Care: Value Uncertainty and Willingness to Pay. Value in Health, 2002, 5, 67-70.	0.3	7
59	Access to Dental Care Services for Medicaid Children: Variations by Urban/Rural Categories in Illinois. Journal of Rural Health, 2002, 18, 512-520.	2.9	30
60	Analysis of the Use of Digoxin Immune Fab for the Treatment of Non-Life-Threatening Digoxin Toxicity. Journal of Cardiovascular Pharmacology and Therapeutics, 2000, 5, 77-85.	2.0	15